Harbin Pharmaceutical’s $300 Million Investment in GNC Holdings

Ropes & Gray Advises Harbin Pharmaceutical in a $300 Million Strategic Investment and China Joint Venture with GNC Holdings, Inc.

In addition, GNC and Harbin Pharmaceutical have agreed to form a joint venture for the manufacturing, marketing, sale and distribution of GNC-branded products in China. The transaction is expected to close in the second half of 2018, subject to customary closing conditions.

Harbin Pharmaceutical Group Co., Ltd. develops and manufactures a variety of medicines, preparations, Chinese traditional medicines, healthcare products, and biopharmaceuticals. The company, led by Zhang Zhenping, Wu Zhijun and Sha Mei, in 2016 recorded $1.882 Billion Revenues.

The Ropes & Gray team was led by corporate partners Michael Littenberg (Picture), Jieni Gu and Daniel Yeh based in the New York, Shanghai and Hong Kong offices.

Involved fees earner: Michael Littenberg – Ropes & Gray; Jieni Gu – Ropes & Gray; Daniel Yeh – Ropes & Gray;

Law Firms: Ropes & Gray;

Clients: Harbin Pharmaceutical Group Co., Ltd.;


Author: Michael Patrini